Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

14.57 +0.25 (+1.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

BioNTech Surges On Summit's Coattails. But Can They Take On Merck? ↗

April 23, 2025

BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.

Via Investor's Business Daily

Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday ↗

April 23, 2025

Via Benzinga

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

April 23, 2025

From Summit Therapeutics Inc.

Via Business Wire

This Company's Co-CEOs Just Bought More Shares. Should You? ↗

April 23, 2025

Via The Motley Fool

In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio? ↗

April 20, 2025

Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.

Via Benzinga

Top 3 Health Care Stocks You May Want To Dump This Quarter ↗

April 15, 2025

Via Benzinga

Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX ↗

April 13, 2025

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

Via Stocktwits

Topics Animal Testing

April 13, 2025

Last week's top performers: SMMT, HMY, AU, CVNA, HOOD, NEM, AVGO, GFI, KGC, CEG. Are they in your portfolio? #stockmarket #investing

Via Benzinga

3 Magnificent Stocks That Could Double or More by 2030 ↗

April 12, 2025

Via The Motley Fool

Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets ↗

April 10, 2025

Via The Motley Fool

Topics ETFs

PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗

April 10, 2025

Via Benzinga

2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade ↗

April 06, 2025

Via The Motley Fool

Topics Government

3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months ↗

April 03, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy World Trade

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗

March 31, 2025

Via The Motley Fool

Topics Government World Trade

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. ↗

March 31, 2025

Via The Motley Fool

Topics Intellectual Property Retirement

Why Summit Therapeutics Stock Slipped Today ↗

March 26, 2025

Via The Motley Fool

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics ↗

March 24, 2025

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.

Via Benzinga

Is Summit Therapeutics a Millionaire Maker? ↗

March 23, 2025

Via The Motley Fool

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 21, 2025

From Summit Therapeutics Inc.

Via Business Wire

This Unstoppable Biotech Stock Just Became an Even Better Buy ↗

March 19, 2025

Via The Motley Fool

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

March 17, 2025

From Summit Therapeutics Inc.

Via Business Wire

Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗

March 16, 2025

Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro...

Via Benzinga

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 14, 2025

From Summit Therapeutics Inc.

Via Business Wire

Why Summit Therapeutics Stock Was Winning This Week ↗

March 14, 2025

Via The Motley Fool

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year ↗

March 13, 2025

Via The Motley Fool

2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger ↗

March 10, 2025

Via The Motley Fool

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

February 28, 2025

Via Benzinga

Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown ↗

February 24, 2025

Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.

Via Stocktwits

Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday? ↗

February 24, 2025

The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.

Via Benzinga

Topics Stocks

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

February 24, 2025

From Summit Therapeutics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.